GSK reports promising early results in ovarian and womb cancer drug trial

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, steps up drug development efforts at the group.

The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.